Promoter hypermethylation is an important means for the transcriptional repression of a number of cancerassociated genes. However, the underlying mechanism of this aberration in cancer remains unclear. Here, we examined 5' CpG island methylation status and expression of the p14 ARF , p16 INK4a and RASSF1A tumor suppressor genes, and investigated the relationship of these factors with the mRNA expression of DNA methyltransferases (DNMTs) and/or methyl-CpG-binding proteins (MBPs) in 30 lung cancer cell lines including 12 small cell lung cancers (SCLCs) and 18 non-small cell lung cancers (NSCLCs). When b-actin was used as an internal control, the mRNA expression of three DNMTs (DNMT1, DNMT3A, and DNMT3B) and five MBPs (MBD1, MBD2, MBD3, MBD4, and MeCP2) was upregulated in SCLC, while only that of DNMT1, DNMT3B and MBD3 was upregulated in NSCLC, compared with normal lung tissues. However, when normalized using proliferating cell nuclear antigen (PCNA) as an internal control, these differences disappeared or diminished; there was even a significant reduction in the expression ratios of DNMT1, MBD2 and MeCP2 in SCLC and DNMT1, MBD2 and MBD4 in NSCLC. Furthermore, although significant correlations between PCNA expression and mRNA expression levels of the three DNMTs and four of the MBPs (excluding MeCP2) were observed, there was no obvious correlation between promoter hypermethylation of these tumor suppressor genes and the expression level of any of the DNMTs or MBPs. Our results suggest that upregulation of DNMTs and MBPs probably reflects an increased cell proliferation in human lung cancers and that there are likely to exist gene-specific mechanisms for epigenetic gene silencing.
Introduction
Human lung cancers show many chromosomal abnormalities including deletions at 3p, 9p21, 13q14 and 17p13 (Sekido et al., 1998a) . According to Knudson's classical two-hit theory, gene mutations and chromosomal deletions are two major mechanisms for the inactivation of tumor suppressor genes (Knudson, 1971) . This theory has been amply confirmed by simultaneous findings of point mutations of p53 and chromosomal deletions of 17p13, where p53 is located, in many lung cancers (Greenblatt et al., 1994) . Meanwhile, although Rb has been shown to be inactivated genetically in familial retinoblastoma and small cell lung cancers (SCLCs) (Francois et al., 1975; Harbour et al., 1988; Horowitz et al., 1990) , one copy of Rb can be silenced by promoter hypermethylation in some sporadic retinoblastomas (Greger et al., 1989) . This finding provided the first example of an alternative non-mutational pathway for inactivation of tumor suppressor genes.
The p16 INK4a tumor suppressor gene, which is located on 9p21, is known to be frequently inactivated in many human malignancies including lung, breast and esophageal cancers (Hamada et al., 2000; Hayashi et al., 1994; Xu et al., 1994; Zhou et al., 1994) . p16
INK4a is expressed from a complex locus, with an alternative promoter and alternative reading frame encoding p14 ARF , which has also been shown to be a tumor suppressor gene. Both genes have a distinct 5' exon, E1a and E1b, respectively, which is spliced into common exons E2 and E3 Stone et al., 1995) . p16
INK4a encodes a cyclin-dependent kinase (CDK) inhibitor that restrains the cell cycle by preventing phosphorylation and inactivation of Rb, and has been found to be inactivated either genetically (mainly homozygous deletion) or epigenetically (promoter hypermethylation) in 50% of non-small cell lung cancers (NSCLCs) and but not in SCLC (Esteller et al., 2001; Gazzeri et al., 1998; Kim et al., 2001; Shapiro et al., 1995; Zo¨chbauer-Mu¨ller et al., 2001) . Although p14 ARF is not a CDK inhibitor and has no sequence homology to two other CD inhibitor genes products, p15
INK4b or p16 INK4a , it can induce cell cycle arrest both in G1 and G2 by binding to the MDM2-p53 complex and preventing p53 degradation (Stott et al., 1998) . Furthermore, loss of nuclear staining for p14 ARF has been reported in 65% of SCLCs and 25% of NSCLCs (Gazzeri et al., 1998) . Thus, p14 ARF and p16 INK4a are involved in two major cell cycle regulatory pathways, referred to as the p53 and Rb pathways, respectively, and are also frequently inactivated in human lung cancer (Sanchez-Cespedes et al., 1999) .
The Ras association domain family 1 (RASSF1) gene was cloned from lung tumor suppressor locus 3p21.3 and consists of two major alternative transcripts, RASSF1A and RASSF1C (Burbee et al., 2001; Dammann et al., 2000) . Although this gene is infrequently mutated, epigenetic inactivation of RASS-F1A, but not RASSF1C, has been demonstrated in 30% of primary NSCLCs and 79% of primary SCLCs (Burbee et al., 2001; Dammann et al., 2001) . Furthermore, transfection of RASSF1A suppressed the growth of lung cancer cells in vitro and in nude mice, suggesting that RASSF1A is a candidate as a tumor suppressor gene for lung cancer development (Burbee et al., 2001; Dammann et al., 2000) .
Although there is evidence for epigenetic gene silencing of tumor suppressor genes and its contribution to tumorigenesis in lung cancer (Esteller et al., 1999; Kashiwabara et al., 1998; Merlo et al., 1995; Zo¨chbauer-Mu¨ller et al., 2001) , the underlying mechanism for the de novo methylation of tumor suppressor genes in cancer cells remains unclear. Recently, several potential mechanisms have been proposed (Tycko, 2000) . These include (1) primary hypermethylation due to overexpression of DNA methyltransferases (DNMTs), (2) gain of methylation secondary to overexpression of transcriptional repressors, (3) gain of methylation secondary to loss of transcriptional activators, and (4) interallelic transfer of methylation via gene pairing. In the primary hypermethylation model, the question of whether or not total DNMT activity is increased in cancer cells remains contentious (El-Deiry et al., 1991; Issa et al., 1993; Lee et al., 1996; Mizuno et al., 2001; Saito et al., 2001) .
Transcriptional inhibition by DNA methylation has been shown to be caused by two mechanisms, one of which is direct interference with the binding of transcriptional factors (Tate and Bird, 1993) and the other recruiting of methyl-CpG-binding proteins (MBPs), which inhibit the binding of transcriptional factors to the promoter regions (Fujita et al., 1999; Meehan et al., 1989) . Since most transcriptional factors do not have CpG dinucleotides within their binding sites, the silencing by DNA methylation is believed to be largely mediated by the binding of MBPs to methylated CpG dinucleotides. To date, a maintenance methyltransferase, DNMT1, two de novo new methylases, DNMT3A and DNMT3B, and five MBPs, including MeCP2, MBD1, MBD2, MBD3, and MBD4, have been described (Cross et al., 1997; Hendrich and Bird, 1998; Lewis et al., 1992) . We hypothesized that abnormal expression of the three DNMTs and/or five MBPs might contribute to aberrant de novo hypermethylation of the p14 ARF , p16 INK4a and RASSF1A tumor suppressor genes in lung cancer. In this study, we examined the relationship between the promoter methylation status and expression of these three genes and the expression of DNMTs and MBPs in 30 lung cancer cell lines including 12 SCLCs and 18 NSCLCs.
Results
Homozygous deletions and promoter methylation status of p14 ARF , p16 INK4a and RASSF1A
For the initial step of searching for the potential underlying mechanisms for transcriptional silencing by de novo promoter hypermethylation in lung cancer, we examined the comprehensive hypermethylation profile of the p14 ARF and p16 INK4a tumor suppressor genes in 12 SCLC and 18 NSCLC cell lines. First, PCR analysis detected no amplification of products for both p14 ARF and p16
INK4a in six out of 18 NSCLC cell lines (NCI-H838, NCI-H1466, A549, NCI-H2122, NCI-H460, and NCI-H322) ( Table 1 and Table 2 ). To determine whether the absence of PCR amplified band was due to homozygous deletion we performed Southern blot analysis and confirmed that these cell lines were homozygously deleted at this locus (data not shown). Next, the methylation status of the promoter regions was analysed by bisulfite genomic sequencing, which allowed a precise assessment of the methylation status in each CpG nucleotide ( Figure 1 and Table 2 ). Among the remaining 24 lung cancer cell lines, no methylation of the p14 ARF gene promoter was found, indicating that promoter hypermethylation of p14 ARF is rare in lung cancer. Meanwhile, the promoter region of p16
INK4a was almost entirely methylated in one SCLC and seven NSCLC cell lines among the 24 cell lines (Table 2) .
We also re-analysed RASSF1A by bisulfite genomic sequencing. Except for the H740 SCLC cell line, which has been shown to be homozygously deleted at the 3p21 RASSF1 locus (Sekido et al., 1998b; Wei et al., 1996) , we confirmed that all the other 11 SCLC cell lines and 16 of 18 NSCLC cell lines were fully (14 cell INK4a showed no p16 INK4a transcripts. As previously shown, RT -PCR analysis for RASSF1A detected two products, with the 223 bp-product corresponding to RASSF1F and the 330 bp-product to RASSF1A (Burbee et al., 2001) . RASSF1A was expressed in all normal lung tissues, two NSCLC cell lines with unmethylated RASSF1A promoter, NCI-H2009 and NCI-H2347, and a SCLC cell line with a methylated promoter, NCI-H526. The expression level of NCI-H526 was low compared with those of the normal lung tissues or the other two cell lines (Table 2 and Figure 2) . None of the 27 cell lines with methylated promoter except NCI-H526 expressed RASSF1A transcripts (Table 2 and Figure 2 ). mRNA expression levels of DNMTs and MBPs normalized to b-actin and PCNA To clarify the role of three DNMTs (DNMT1, DNMT3A, and DNMT3B) and five MBDs (MeCP2, MBD1, MBD2, MBD3, and MBD4) in aberrant promoter hypermethylation, we examined their expressions in 30 cell lines and four normal lung tissues by semi-quantitative RT -PCR analysis (Figures 3 and 4) . The expression level was normalized with two genes, b-actin and proliferating cell nuclear antigen (PCNA), both of which have been used by other groups for normalization of DNMTs; the former is thought to be a housekeeping gene, and the latter a proliferation marker. As shown in Figure  4 , when b-actin was used as an internal control, the mRNA expression ratio of the three DNMTs and five MBPs in SCLC and that of DNMT1, DNMT3B and MBD3 in NSCLC were significantly higher than in normal lung tissue. However, when PCNA was used as an internal control, these differences disappeared or diminished. In fact, the expression The expression of all DNMTs and MBPs in SCLC cell lines was significantly higher than that in NSCLC cell lines when b-actin was used as the normalization gene (Figure 4) . This difference also disappeared or diminished when PCNA was used for the normalization gene (Figure 4) The expression of PCNA in SCLC cell lines and NSCLC cell lines was approximately fourfold and twofold higher, respectively, than in normal lung tissues (Figure 3) . Furthermore, statistically significant correlations were observed between the expression of PCNA and that of the three DNMTs and four of the MBPs (excluding MeCP2) (DNMT1 and PCNA (r=0.506, P=0.0019), DNNT3A and PCNA (r=0.434, P=0.0097), DNMT3B and PCNA (r=0.509, P=0.0018), MBD1 and PCNA (r=0.678, P50.0001), MBD2 and PCNA (r=0.506, P=0.0019), MBD3 and PCNA (r=0.625, P50.0001), and MBD4 and PCNA (r=0.43, P=0.0104)). In addition, we found a strong correlation among the three DNMTs in 30 cell lines (DNMT1 and DNMT3A (r=0.556, P=0.0005), DNMT1 and DNMT3B (r=0.699, P50.0001) and DNMT3A and DNMT3B (r=0.76, P50.0001).
Relationship between promoter hypermethylation and expression level of DNMTs and MBPs
Since none of the cell lines showed methylation of p14 ARF , we analysed the relationship between the methylation status of p16 INK4a , and RASSF1A and the expression of DNMTs and MBPs. Because inactivation of p16 INK4 has been shown to be frequent in NSCLC cell lines, but to be rare in SCLC, we limited the cell lines analysed for p16 INK4 to NSCLC cell lines. No significant difference in the expression of DNMTs and MBPs was found between seven promoter methylated NSCLC cell lines and five unmethylated NSCLC cell lines for p16 INK4a , or between 14 cell lines with completely methylated promoters and 15 incompletely methylated cell lines for RASSF1A (data not shown). 
Discussion
The present data show that the mRNA expression levels of three DNMTs and all MBPs except MeCP2 were significantly higher in both SCLC and NSCLC cell lines than in normal lung tissues, when b-actin was used as a normalization gene. However, when normalized with PCNA these significant differences disappeared or diminished; the expression of DNMT1 and MBD2 was even significantly lower in lung cancer cell lines than in normal lung tissues. These results suggest that the expression levels reflect the increased proliferation of cancer cells compared with that of normal lung tissues. Meanwhile, the promoter methylation status of the p14 ARF , p16 INK4a and RASSF1A genes was not correlated with the expression of any of the DNMTs and MBPs.
Although the expression of DNMTs has been most extensively studied in colorectal cancers, the exact degree of overexpression of DNMTs in colorectal cancer remains controversial (El-Deiry et al., 1991; Issa et al., 1993; Lee et al., 1996) . Lee et al (1996) demonstrated that re-analysis of the expression of DNMT1 in colorectal cancer using the cell proliferation marker as an internal control abolished the significant differences which were observed in normalization by housekeeping genes. Furthermore, another group has shown that not only DNMT1, but also DNMT3A and DNMT3B were not over-expressed in colorectal cancer when the cell proliferation gene was used for normalization (Eads et al., 1999) . In this study, we obtained results consistent with these for DNMT and MBP expression in lung cancer cell lines. Furthermore, our finding that the expression of DNMTs is significantly correlated with PCNA expression supports the notion that upregulated expression of DNMT might be a simple reflection of increased cancer cell proliferation. On the other hand, a recent study has shown that DNMTs were significantly overexpressed in hematologic malignancy with normalization by both housekeeping and cell proliferation marker genes (Mizuno et al., 2001) , suggesting that DNMTs really are over-expressed in some types of malignancies.
We found that expression of all DNMTs and MBPs in SCLC cell lines was significantly higher than in NSCLC cell lines when b-actin was used as a normalization gene. However, this difference also disappeared or diminished when PCNA was used for the normalization gene. Since expression of PCNA in SCLC cell lines was approximately twice as high as that in NSCLC cell lines, we considered that this difference might simply reflect the difference in the cell proliferation rate between SCLC and NSCLC cell lines.
Although PCNA has been used in numerous studies as a cell proliferation marker for human cancer cells, it may not always reflect the rate of cell proliferation exactly, because PCNA expression is not a specific marker for the rate of cell proliferation. Thus, it is possible that the expression levels of DNMTs and MBPs are elevated relative to the rate of proliferation, although we showed that they are not elevated relative to PCNA. Furthermore, it is also possible that PCNA is elevated coordinately with the DNA methylating enzymes and that they are all elevated in lung cancer cells.
We did not find any apparent correlation between the methylation status of tumor suppressor genes in lung cancer and the expression levels of DNMTs and MBPs. Three studies have examined the relationship between methylation status of tumor suppressor genes and the expression levels of DNMTs in colorectal cancer, gastric cancer, and hepatocellular carcinoma (Eads et al., 1999; Kanai et al., 2001; Saito et al., 2001) . One study showed a significant association between methylation status and overexpression of DNMT3B in colorectal and gastric cancers, using histone H4 proliferation marker as an internal control . However, the other two studies failed to show any significant correlation in hepatocellular carcinoma and colorectal cancer (Eads et al., 1999; Saito et al., 2001) . It is unclear whether aberrant expression of DNMTs and/or MBPs in cancer cells is involved in local hypermethylation of tumor suppressor genes at distinct loci. In the present study, intergenic variations in the aberrant methylation status such as a discrepancy of promoter methylation between p14 ARF and p16
INK4a were observed, suggesting that the aberrant promoter hypermethylation of the tumor suppressor genes might be caused by locally restricted and gene-specific regulations involving DNMTs or MBPs or unidentified transcription factors.
We tested whether the methylation status of tumor suppressor genes is associated with the mRNA expression levels of DNMTs and MBPs, but not with the levels of the protein products. Since many gene products are regulated by transcriptional, translational and post-translational mechanisms, a future study is needed to investigate the association of enzymatic activities of these gene products with the methylation status of tumor suppressor genes. In addition, since we analysed only established cancer cell lines but not surgically resected tumor samples, the exact timing and mechanisms of the evolution of the aberrant promoter methylation patterns in vivo are still unclear. It is also possible that the methylation changes might occur with transiently upregulated DNMTs or MBPs when the tumors developed in vivo, then the aberrant methylation patterns were maintained thereafter with the relatively low, but still sufficient levels of the enzymes which we detected in the cell lines. Thus, it remains to be studied in the future whether primary lung tumors overexpress DNMTs and MBPs in vivo.
In conclusion, the expression of DNMTs and MBPs in cancer cell lines compared with normal lung tissue probably reflects the increased cell proliferation of cancer cells, and the promoter methylation status of the p14 ARF , p16 INK4a and RASSF1A genes was not correlated in the present study with expression of any of the DNMTs or MBPs. To clarify the possible mechanisms for the de novo hypermethylation of tumor suppressor genes, investigation of more locally restricted and gene specific regulation will be required.
Materials and methods

Cell lines
The tumor cell lines have been described and were deposited at the American Type Culture Collection (Phelps et al., 1996) . The 30 cell lines used in this study included 12 SCLCs and 18 NSCLCs. Genomic DNA and total RNA were prepared from cell lines using standard techniques (Sambrook et al., 1989) . Random-primed, first strand cDNAs were synthesized from 3 mg of total RNAs using three units of Superscript II according to the manufacturer's instructions (Life Tech. Inc., Rockville, MD, USA). Four non-cancerous lung tissues were obtained from surgically resected specimens from four patients with lung cancer. Tissues were collected after obtaining Institutional Review Board approval and signed informed consent from patients.
Bisulfite genomic sequencing
Bisulfite modification of genomic DNA was performed as reported by Herman et al. (1996) with minor modifications. Briefly, after 1 mg of genomic DNA in a volume of 50 ml was denatured with NaOH (final concentration, 0.3 M), 30 ml of 10 mM hydroquinone (Sigma, St. Louis, MO, USA) and 520 ml of 3.2 M sodium-bisulfite (Wako, Osaka, Japan) were added, and then samples were incubated at 558C for 16 h. Modified DNA was purified using a Wizard DNA Purification Kit (Promega, Madison, WI, USA) followed by ethanol precipitation, and then was used as a template for PCR. Primer sequences of p14 ARF , p16 INK4a and RASSF1A, annealing temperatures, and expected PCR product sizes are summarized in Table 1 . PCR products of the three genes had sequences containing the transcription initiation sites and 15 or 16 CpGs between the primers (Figure 1) . The reaction was performed in a 50-ml mixture containing 106PCR buffer (Qiagen), deoxynucleotide triphosphate (1.25 mM), primers (final concentration, 1.0 mM), one unit of HotStar Taq (Qiagen), and bisulfite-modified DNA (*20 ng). Amplification was carried out in a 9700 Perkin-Elmer Thermal Cycler. PCR products were sequenced using an Applied Biosystems model 377 DNA sequencer (Perkin-Elmer Cetus, Norwalk, CT, USA) as previously described (Sato et al., 2000) .
Reverse transcription polymerase chain reaction
To assure exponential amplification, we carried out preliminary RT -PCR as follows. The first strand cDNAs were serially diluted and used as templates. Preliminary PCR was performed with three different numbers of cycles, starting from 25 cycles for b-actin and 28 cycles for other genes, in increments of two to three cycles to find the linear range of amplification. PCR products were separated by 3% agarose electrophoresis, visualized on a UV transilluminator and photographed. The signal intensity of each PCR product was estimated by the NIH image 1.61 program. The minimum number of cycles, at which the signal of the PCR product amplified from most diluted cDNA was detectable, and signal intensities of the three PCR products were proportional to the amounts of the template cDNAs, was taken as the cycle number for semiquantitative RT -PCR analysis. The primer sets used, number of cycles, annealing temperatures and product sizes are shown in Table 1 . The reaction was performed in a 25-ml mixture containing 106PCR buffer (Qiagen), deoxynucleotide triphosphate (1.25 mM), primers (final concentration, 1.0 mM), one unit of HotStar Taq (Qiagen), and one ml of cDNA. In semiquantitative RT -PCR, the intensity of the amplified bands of each gene was indicated as the proportional ratio to the minimum intensity observed in the 30 cell lines and four normal lung tissues. We used both b-actin (housekeeping control) and PCNA (a cell proliferation marker) as internal controls to normalize the expression of DNMTs and MBPs.
Southern blot analysis
Five mg of high-molecular-weight DNA from each cell line was digested with EcoRI or XbaI, electrophoresed in 0.7% agarose gel, and transferred to Hybond N+ (Amersham, Arlington Heights, IL, USA) as described previously (Sekido et al., 1992) . Hybridization and washing were performed using standard techniques (Sambrook et al., 1989) . Exon E1a and exon E1b cDNA fragments were used as DNA probes for the p16
INK4a and p14 ARF genes, respectively.
Statistical analysis
Differences in the expression level of DNMTs and MBPs between cancer cell lines and normal tissues were analysed by non-paired t test. The strength of the association between the expression levels of DNMTs, MBPs and PCNA was calculated by Pearson's correlation coefficient.
Abbreviations SCLC, small cell lung cancer; CDK, cyclin-dependent kinase; NSCLC, non-small cell lung cancer; RASSF1, Ras association domain family 1; DNMT, DNA methyltransferase; MBP, methyl-CpG-binding protein; PCNA, proliferating cell nuclear antigen.
